PTC Therapeutics CEO Klein sells $705,722 in company stock By Investing.com

Matthew B. Klein, Chief Executive Officer and a Director of PTC Therapeutics, Inc. (), sold 10,292 shares of the company’s common stock on August 4, 2026. The shares were sold at a price of $68.57 per share, totaling $705,722. The stock has since risen to $70.85, with the company carrying a market capitalization of $5.91 billion. According to InvestingPro analysis, PTCT currently trades above its Fair Value, placing it among the platform’s most overvalued stocks.

The transaction represents shares automatically sold to satisfy tax withholding obligations. This “sell to cover” election was entered into upon acceptance of the grant, in connection with the vesting of 25,000 Restricted Stock Units (RSUs) from an August 1, 2025 grant of 75,000 RSUs.

Following this transaction, Mr. Klein beneficially owns 383,868 shares of PTC Therapeutics common stock. This total includes 162 shares of common stock acquired under the Issuer’s employee stock purchase plan for the period ended June 30, 2026. An InvestingPro tip notes that analysts predict the company will be profitable this year, with earnings per share forecast at $1.80 for 2026. For deeper insights, including 12 additional ProTips and comprehensive Pro Research Reports covering PTCT and 1,400+ other US equities, visit InvestingPro.

In other recent news, PTC Therapeutics reported impressive second-quarter 2026 results, surpassing Wall Street expectations with earnings of $0.92 per share on revenue of $361 million. This performance significantly exceeded analysts’ forecasts of $0.32 per share and $293.1 million in revenue. The company’s strong sales were largely attributed to Sephience, which contributed to record revenue figures. PTC Therapeutics also increased its full-year revenue outlook, highlighting continued momentum in Sephience and international growth. Additionally, the company reported having $2.23 billion in cash at the end of the quarter, providing flexibility for future investments and potential deals. Despite the positive earnings report, the stock showed little change in after-hours trading. Analysts and investors may be considering the strong quarterly performance against future execution challenges. The company’s product revenue more than doubled compared to the previous year, with Sephience alone generating $161 million, marking a 21% increase from the first quarter.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.